AstraZeneca in AI collaboration with Immunai to inform cancer …
WEB1 day ago · AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said ...
Israel's Immunai expands strategic tie with AstraZeneca
WEB1 day ago · The agreement is worth an initial $18 million to Immunai, developer of an AI-based model for making drug development more efficient. Israeli company Immunai, a developer of AI-based tools for improving drug discovery processes, has announced a strategic agreement with pharmaceuticals company AstraZeneca.Immunai will receive $18 million from AstraZeneca at the initial stage of the research, but ...
Immunai signs $18M collaboration with AstraZeneca to make …
WEB1 day ago · AstraZeneca. Israeli startup Immunai, which has developed a system that maps the human immune system with single-cell granularity, has announced a multi-year collaboration with AstraZeneca. Under the terms of the agreement, Immunai is set to receive $18 million for the initial phase of the collaboration. The collaboration will …
Immunai and AstraZeneca's $18 Million AI Collaboration to …
WEB1 day ago · Immunai will leverage its AI immune system model, the IDE, to improve clinical trial success rates. AstraZeneca may expand the collaboration’s length and scope after the initial phase. This initiative reflects a growing trend of using AI to transform clinical development processes and expedite access to innovative therapies for cancer patients.
Improving drug development with a vast map of the immune system
WEBApr 11, 2024 · Immunai, founded by two researchers from MIT, is helping pharmaceutical companies identify the patients that stand to benefit most from new treatments. The human immune system is a network made up of trillions of cells that are constantly circulating throughout the body.
Biotech firm Immunai raises $215 million, valuation above $1 bln
WEBOct 27, 2021 · U.S.-Israeli biotech firm Immunai said on Wednesday it raised $215 million in a private funding round at a valuation of more than $1 billion. The round was led by Koch Disruptive Technologies ...
Immunai and Baylor College of Medicine Provide Updated Interim …
WEBMay 15, 2023 · Investigators from Baylor College of Medicine (BCM) in collaboration with Immunai have published results from a clinical study in which Immunai’s tech.
Immunai to collaborate with AstraZeneca on oncology clinical …
WEB1 day ago · Immunai is set to receive $18 million for this initial phase, with AstraZeneca retaining an option to expand the length and scope of the collaboration. “This collaboration is a natural ...
Newsroom - Immunai
WEBHeadquarters. Immunai 430 E 29th St, New York, NY 10016. press@immunai.com; info@immunai.com
Immunai announces a $215M Series B as its ‘immune cell
WEBOct 27, 2021 · Immunai has been building a massive data set of clinical immunological information. It combines genetic information, along with other data like epigenetic changes or proteomics (the study...
- Some results have been removed
Skip to content